Background. Elevation of haemoglobin (Hb) with recombinant erythropoietin (rHuEpo) in patients with chronic renal failure has raised concern of increased risk of thromboembolic diseases. In this study, a substudy of the Scandinavian multicentre trial, we examined the in¯uence on haemostatic parameters of normalization of Hb levels from subnormal levels in patients with chronic renal failure. Methods. Twenty-six patients, 17 males (before study start Hb 113"6 gul) and nine females (Hb 111"8 gul), with end-stage renal disease were included. Both dialysis and predialysis patients were included. After 3 months of rHuEpo therapy Hb levels reached 136"14 gul for males and 128"13 gul for females, and after 1 year 142"11 gul and 126"14 gul respectively. The increase in Hb was signi®cant both at 3 months and 1 year, compared to baseline. At baseline, after 3 months and 1 year haemostatic and prothrombotic parameters were measured, including prothrombin complex test, activated partial thromboplastin time, platelet aggregation and retention, von Willebrand factor antigen, antithrombin, protein C, total and free protein S, activated protein C resistance, FV±Leiden mutation, D-dimers, plasminogen activator inhibitor-1 and prothrombin fragments 1q2 (PF 1q2). Results. The only statistically signi®cant change was a transient decrease in total levels of protein S at 3 months from 131 to 120% (Ps0.0093). The free and active form of protein S showed no signi®cant change. After 1 year the difference was not seen. Conclusions. Apart from a transient and clinically insigni®cant decrease in total protein S, we found no prothrombotic changes after normalization of Hb from subnormal levels. Our ®ndings indicate that rHuEpo treatment may aim at normalizing Hb levels without signi®cant effects on haemostatic parameters in patients with chronic renal failure compared to patients with subnormal Hb levels.
Introduction
Blood haemostasis is carefully controlled by a complex interaction between platelets, the coagulation cascade, coagulation inhibitors, ®brinolysis, and the vascular endothelium. Patients with chronic renal failure often exhibit a bleeding tendency and multiple haemostatic disorders w1x. The changes in haemostatic conditions are evident as glomerular ®ltration rate (GFR) falls below 30 mlumin. The increased bleeding tendency has been regarded useful in preventing thrombosis of AV ®stulae and clotting in the dialysis system. Introduction of recombinant erythropoietin (rHuEpo) in the therapy of renal anaemia in the 1980s has dramatically changed the quality of life of patients with chronic renal failure. Among the adverse effects possibly associated with the use of rHuEpo in patients with chronic renal failure, a risk of thrombosis of the vascular access has been reported w2,3x. Shortening of bleeding time w4x, a rise in whole-blood viscosity w5x, increased platelet count w6x, improvement of platelet function w7, 8x, spontaneous platelet aggregation w9x, impairment of ®brinolysis w10x, and a decrease in natural coagulation inhibitors w11,12x have been reported after rHuEpo therapy. Although rHuEpo may induce these prothrombotic changes, it is unclear whether it results in clinically signi®cant thrombotic events w13x.
Furthermore, the increased risk of thrombosis of AV ®stulae remains controversial w14x, but in a recent study, w15x, a higher incidence of ®stula thrombosis was shown in the normal-haematocrit (Hct) group compared to the low-Hct group. Another study could not ®nd any rheological changes that could contribute to an increased risk of access thrombosis in haemodialysis (HD) patients with normal initial Hct before HD w16x.
Because of the risk of side-effects, hypertension, and thrombosis, rHuEpo was initially used with restriction and for many years a subnormal haemoglobin (Hb) level around 100±110 gul was considered to be optimal. The present study is a substudy of the Scandinavian multicentre trial. The aim of this study was to establish if normalization of Hb from subnormal values with rHuEpo in patients with end-stage renal disease caused any prothrombotic changes in haemostatic parameters.
Subjects and methods
This is a substudy of a randomized, prospective, openlabelled, multicentre study comprising 416 patients (age 18±80 years) with end-stage renal disease in Scandinavia, which started in 1995.
Inclusion criteria
Included were: Patients with end-stage renal disease de®ned as predialysis patients with creatinine clearance -30 mlumin not yet on dialysis, patients undergoing regular HD, and patients on continuous ambulatory peritoneal dialysis (CAPD). All patients on dialysis regimen were considered for inclusion. Predialysis patients were included consecutively.
Exclusion criteria
These were: anaemia of causes other than chronic renal failure, B 12 and folic acid de®ciency, uncontrolled hypertension (diastolic blood pressure >100 mmHg), uncontrolled diabetes mellitus, clinically relevant abnormal liver function, severe hyperparathyroidism, and uncontrolled overhydration. Predialysis patients likely to become dialysis-dependent within 1 year were excluded. Salicylic acid and non-steroidal anti-in¯ammatory drugs were postponed 10 days prior to blood tests.
Twenty-six patients (mean age 54 years, range 22±79) at three centres in Sweden (Malmo È , Lund, and Uppsala) were included. Seventeen males with a mean age of 57 years (range 22±79) and nine females with a mean age of 50 years (range 36±71) participated. Eleven patients were being treated by HD, two were on CAPD, and 13 were predialysis patients (Table 1) . Predialysis patients and those on CAPD were recruited from Uppsala and patients on HD from Malmo È and Lund. The predialysis patients presented a mean GFR of 16 mlumin (range 6±24). All patients, except ®ve of the predialysis patients, were on rHuEpo treatment at the start of the study. Furthermore, all patients were evaluated by liver tests every 12 months and revealed normal values at the start of the study and no signi®cant changes during the study. None of the patients suffered from viral hepatitis according to tests for hepatitis B and C. Dialysis patients (HD and CAPD) in our study ful®lled the criterion of adequate dialysis treatment (KtuV >1.2 for HD and a weekly creatinine clearance > 55 mlumin for CAPD). None of the CAPD patients and only two of the predialysis patients had a vascular access at the start of the study.
Study protocol
Before inclusion the patients demonstrated stable Hb in the subnormal range for at least 3 months with or without rHuEpo treatment. Inclusion criteria was Hb in the range 90±110 gul for females and 100±120 gul for males during the run-in period. Iron de®ciency, serum ferritin -100 mgul anduor transferrin saturation -20%, was treated with intravenous iron sucrose (Venofer 1 ) or oral iron supplementation. Planned study time was 1 year. The regimen of rHuEpo administration remained patient-speci®c, i.e. intravenously (2±3 times weekly) or subcutaneously (1±3 times weekly), according to the route of administration at baseline. The weekly rHuEpo dose was increased to reach the new steadystate Hb within 2±3 months. The dose escalation was tailored to a smooth Hb increase of 10±15 gul per month. The initial dose increment was in the range of 50%. The goal for rHuEpo treatment was a Hb level of 125±140 gul in females and 145±160 gul in males, 2±3 months after study start and during the rest of the study.
Evaluations
In HD patients all laboratory investigations were performed predialysis and mid-week. Anticoagulation requirements during dialysis were recorded. All adverse events, hospitalizations, coronary events and treatments, thromboses at vascular access sites, or procedures involving vascular access site, transfusions, and deaths were recorded.
All haemostatic parameters were analysed at the Department for Coagulation Disorders at Malmo È University Hospital. Platelet aggregation, platelet retention, and bleeding time were only performed in patients (ns10) from Malmo È and Lund, as these tests had to be done while the patients visited the laboratory.
In addition to Hb, Hct, and platelet count, the following haemostatic parameters were measured before the study start, at 3 months, and at 1 year; prothrombin complex test, activated partial thromboplastin time (APTT), platelet aggregation and retention, bleeding time (Ivy), von Willebrand factor antigen (VWF.Ag), multimeric structure of VWF, ®brinogen, antithrombin (AT), protein C, total and free protein S, activated protein C resistance (APC resistance), FV±Leiden mutation analysis, D-dimers, F VII, plasminogen activator inhibitor-1 (PAI-1), and prothrombin fragments 1q2.
Three patients on medication with vitamin K antagonists were excluded from evaluation of APTT, prothrombin complex test, F VII, protein C, protein S, and prothrombin fragments 1q2.
Methods
Blood sampling Venous blood for plasma samples was collected in silicone-coated Vacutainer 1 tubes (Becton Dickinson) with a volume of 5 ml, containing 0.5 ml of 0.129 molul sodium citrate. Platelet-poor plasma (PPP) for coagulation analyses was obtained after centrifugation at 2000 g for 20 min. Plasma was frozen immediately and kept at À708C until assessed. Samples from Uppsala were transported by express service to Malmo È at À708C. When arriving at Malmo È the samples were immediately taken care of at the Department for Coagulation Disorders and kept at À708C until analysed. No delay was accepted. This transportation routine has been approved by the Department for Coagulation Disorders in Malmo È . Blood tubes for analysis of platelet retention were not centrifuged. They were placed in a test tube rack in room temperature for a period of 45±120 min, after which platelet retention was measured. Venous blood for DNA extraction was collected in EDTA tubes. Venous blood for platelet aggregation studies was collected in 10-ml polystyrene tubes containing 1 ml 0.129 molul sodium citrate. Platelet-rich plasma (PRP) was obtained after centrifugation at 275 g for 10 min.
Assays
1. Prothrombin complex test was performed in a Thrombolyzer by a prothrombin±proconvertin method using a reagent containing thromboplastin, calcium 2q ions, and bovine plasma lacking coagulation factors II, VII, and X. The coagulation time is proportional to the levels of factors II, VII, and X in the patient plasma. The coagulation time is compared with dilutions of a reference sample and results are given as %. Normal range 70±130%. 2. The activated partial thromboplastin time (APTT) was tested in a Thrombolyzer according to a standard method. Normal range 24±37 s. 3. Platelets were counted visually by phase microscopy.
Normal range 125±340 3 10 9 ul.
Platelet aggregation was measured in a Lumiaggregometer
(Chrono-Log, Haverton, PA, USA) as described earlier w17x. 5. Platelet retention was measured on citrated venous whole blood with a modi®ed Adeplat S test (Semmelweis, Milan, Italy), as described earlier w17x, (normal range 16±27%). The intra-individual coef®cient of variation (CV) of 10 blood samples taken on one occasion in one healthy volunteer has been found to be 7.1% (mean platelet retention 17.7%, SD 1.25%). The intra-individual day-to-day variation tested in two healthy volunteers has been found to be 8 and 13% respectively w18x. 
Calibration against an international standard
Standard plasma from about 40 healthy subjects was calibrated against a calibrator substance (international standard) for analysis of VWF.Ag, antithrombin, protein C and F VII. Results were expressed as IUuml.
Statistical methods
Each patient served as hisuher own control. Changes from baseline in each patient were evaluated after 3 months and 1 year using non-parametric statistics (Wilcoxon signed rank). In order to avoid mass signi®cance due to multiple variables, we have not chosen to de®ne statistical signi®cance as P-0.05 but rather as P-0.01. All P values are presented.
Correlation between different variables was tested using the Spearman rank correlation test.
Ethics
The investigation was approved by the Ethics Committee of all centres.
Results
Before inclusion mean Hb was 113"7 gul (range 95±123) in both males and females (Table 2) .
Hb-levels after increased doses of rHuEpo are expressed in Table 2 . The increases in Hb levels were signi®cant (P-0.001) at 3 months and 1 year, compared to baseline.
To achieve desired Hb levels, rHuEpo requirements were increased by about 200% at 3 months and 130% at 1 year after study start, compared to baseline doses. Three patients did not respond to increased doses of rHuEpo. In total, seven patients did not reach target Hb at 3 months or 1 year.
Two patients of 26 did not ful®l the 1-year study. One man was excluded after 10 months due to deterioration of his general condition and one woman was excluded after 8 months when pregnancy was detected. These two patients are analysed only at baseline and at 3 months.
Intravenous iron sucrose was administered in 21 of the 26 patients. During the study the administered dose of iron was increased at 3 months by about 150% and 60% at 1 year, compared to baseline.
At baseline four patients were heterozygous for FV-Leiden mutation. None of these exhibited thrombotic events. No other prothrombotic coagulation disorders were found at baseline.
The only signi®cant change was a slight and transient decrease in total protein S occurring 3 months after study start (Table 3) . Total protein S diminished from 131"27 to 120"24% (Ps0.0093). However, the level at baseline was slightly above reference level, and after 3 months was within normal range. After 1 year there was no signi®cant difference compared to baseline levels regarding this parameter. All other haemostatic parameters were unchanged during this 1-year study. We found no signi®cant changes in platelet count and platelet retention during the study. High levels of prothrombin fragments 1q2 were found at all three occassions for blood sampling. After 3 months there was a decrease in these fragments (3.0"2.11 nmolul to 2.4"1.07) but the difference only reached a P value of 0.0496.
In this rather small group of patients (ns26) we observed no vascular access thromboses or other thrombotic events. However, the patients on CAPD had no vascular access and among the predialysis patients only two had vascular access at the start of the study.
In order to establish if the observed change in levels of total protein S were related to the dose of the drug, correlation test between doses of rHuEpo and levels of total protein S was done (not shown). There was no such correlation.
We also excluded those seven patients who did not reach target Hb, 125 gul for women and 145 gul for men, at either 3 months or at 1 year. After this exclusion 19 patients remained. Hb levels are expressed in Table 4 . In this group of 19 patients we found a slight decrease in total protein S from 127"25 to 115"19% after 3 months (Ps0.028). However, our limit for statistical signi®cance was less than 0.01 due to multiple variables. Also after 1 year there was no statistically signi®cant decrease in protein S.
Discussion
The introduction of rHuEpo treatment of uraemic anaemia has markedly improved the quality of life of patients with end-stage renal disease. rHuEpo was used with a restriction due to the fear of side-effects such as hypertension and thrombosis and for many years a subnormal Hb level around 100±110 gul was considered to be optimal. Several studies have addressed the potential effect of rHuEpo treatment on haemostatic variables, but in most studies Hb levels only reached subnormal values w4,6±8x. Many of these found a transient increase in the number of platelets and improved platelet function, but for other haemostatic parameters the results have been contradictory w23x. It should be emphasized that most of these studies compared baseline values without rHuEpo vs post-treatment values aiming at Hb levels of 100±110 gul.
The aim of our study was to establish if normalization of Hb from subnormal values with rHuEpo in patients with end-stage renal disease caused any prothrombotic changes in haemostatic parameters. Therefore this study is different from most other studies with respect to baseline Hb and target Hb.
We included both dialysis and predialysis patients with end-stage renal disease that were anaemic. These two categories may have different haemostatic conditions because the increased bleeding tendency, caused by uraemia, is more pronounced in severe uraemia compared to moderate uraemia, although the exact in¯uence on bleeding parameters at different Values are expressed as mean values, "SD and ranges. Table 3 . Haemostatic parameters at baseline, at 3 months, and at 1 year after normalization of Hb with rHuEpo PAI-1 baseline (0±16 Uuml) 9.7"4.2 (8±22) ns26 PAI-1 after 3 months 9.8"3.5 (8±20) ns26 1.0000 PAI-1 after 1 year 9.2"2.5 (8±16) ns23 1.0000
Values are expressed as mean values, "SD and ranges. uraemic levels is hard to address. It has been shown by Remuzzi et al. w24x that dialysis only partially corrects abnormal bleeding time and platelet retention. It has also been shown that there are no differences between ef®cient haemodialysis and peritoneal dialysis in improving the renal bleeding tendency w25x. The predialysis patients in this study presented a GFR around 16 mlumin and the dialysis patients were adequately dialysed, which means that the range in uraemic level was limited. Furthermore, this study was designed with each patient being hisuher own control, which diminishes the effect of mixing predialysis and dialysis patients. In order to evaluate if these two groups of patients were comparable in haemostatic conditions we compared baseline characteristics of coagulation parameters (except platelet aggregation and retention) in the two groups. However, we found no statistically signi®cant changes between dialysis and predialysis patients. Although the patients were treated in different ways (HD, CAPD, and conservative treatment) they should be comparable with respect to haemostatic disorder. We included patients in two regions at three hospitals. Investigation of platelet function (platelet aggregation and retention and bleeding time) could only be performed in one region. All other haemostatic parameters were analysed in all patients. Thus predialysis patients and those on CAPD (from Uppsala) were not analysed for platelet function, whereas HD patients (from Malmo È and Lund) were analysed for all haemostatic parameters.
Except for a small decrease in total protein S levels at 3 months, we did not ®nd any prothrombotic changes in plasma levels of haemostatic parameters, including platelets. This observed change probably has no clinical signi®cance since the change is small, within normal ranges, and affects only the total amount of protein S. The free and active form of protein S did not change signi®cantly. We speculated that the decrease of protein S at 3 months could be related to relatively high doses of rHuEpo, about 200% above baseline dosage at 3 months compared to 130% at 1 year. However, the lack of correlation between rHuEpo dosage and protein S levels did not support this hypothesis.
To our knowledge there are only limited data from other studies on the effects of normalization of Hb levels with rHuEpo treatment. An American study of patients with clinically evident congestive heart failure or ischaemic heart disease receiving haemodialysis demonstrated higher mortality in the normal-Hct group compared to the low-Hct group. The difference in mortality was not due to increased venous thromboembolism w15x. However, both in the normal-and low-Hct groups the mortality rate decreased at higher Hct values.
In contrast to several other studies, we found no changes in platelet levels or function. One reason for this discrepancy could be that we only measured platelet function in a subset of patients (ns10).
Another reason may be that most other studies did not aim at normalizing Hb and compared those patients treated with rHuEpo with those without treatment. Our observation of a transient decrease of total protein S at 3 months is in parallel with the observation made by Macdougall and co-workers w12x who also found a decrease at 3±4 months.
Other studies have found divergent results concerning haemostatic parameters. A transient reduction of antithrombin, free protein S, plasminogen, and tissue type plasminogen activator in plasma was shown by Vaziri and co-workers w26x. Lai et al. w27x found no signi®cant changes in immunological or functional activities of protein C, protein S, or antithrombin in uraemic patients on CAPD when Hb was increased from 69"13 to 96"13 gul. They found a small but signi®cant change of prothrombin time and APTT within normal range. Clyne and co-workers w8x found no changes of total and free protein S after elevation of Hb from 82"9 to 111"12 gul.
Our ®ndings indicate that Hb levels can be normalized with rHuEpo without signi®cant prothrombotic changes compared to patients with Hb at subnormal levels. These results were based on a 1-year follow-up of patients being their own controls. But this study does not evaluate the difference in haemostatic parameters between patients with severe, untreated anaemia and patients with normalized Hb. Results in this study are in accordance with Tang et al. w23x, who made a literature review and concluded that the effects of rHuEpo on the coagulation cascade are of minimal clinical importance.
Our ®ndings are also supported by the larger Scandinavian multicentre study, of which our work is a substudy, where there was no signi®cant difference in number of vascular access thromboses or other thrombovascular events between subnormal and normal Hb groups. This is also supported by a recently published German study w16x. From our investigation, we conclude that elevation of Hb from subnormal to normal values in patients with uraemic anaemia is achievable without causing signi®cant changes in haemostatic parameters.
